9M 2023 Financial Overview
9M 2023: Business update
Rexulti continues strong growth with
19%
U.S. Rexulti demand¹)
(weekly - TRx)
Global Rexulti revenue
(DKKm)
2022
6
FDA approval
+19%
CER
DKK 2,817m
+18%
CER
+38%
CER
+32%
CER
DKK 3,309m
2023
Age 65+ TRX
4-week average
9M 2022
United States
Europe
9M 2023
International Markets
Rexulti was approved by FDA July 2015 and by the EU Commission July 2018. 1) IQVIA Xponent data, latest datapoint ending October 6, 2023. TRx:
total prescriptions. MDD: major depressive disorder. AADAD: agitation associated with dementia due to Alzheimer's disease. DTC: direct-to-consumer.
LTC: long-term care
REXULTI™
brexpiprazole
tablets
Strong double-digit revenue
growth across all regions
•
•
•
U.S. the main driver of growth
Other key markets, such as Canada and
Brazil also growing strongly
Rexulti AADAD U.S. launch
Rexulti achieved over 2% TRX market share
for the first time
Significant infliction in 65+ TRxs confirmed by
patient claims data
•
Even stronger uptake in patients aged 85+
and LTC facilities
•
Branded DTC campaign was launched on
October 9View entire presentation